Monographie - Dacarbazine

آخر تحديث :
19/11/2024

Dacarbazine

التركيب الكيميائي

حجز الاسم التجاري

تحذير الأسماء التجاريه المختلفه قد تحتوي علي محتوي إضافات مختلفة حسب الدوله و المعمل

Acocarb	المكسيك
Celdaz	الهند, بيرو
Dabaz	الهند
Dacarb	الهند, بيرو
Dacarba	الهند
Dacarbaz	تركيا
Dacarbazin	النمسا, بولندا, ماليزيا, هنغاريا
Dacarbazina	إسبانيا, الأرجنتين, الإكوادور, تشيلي, كولومبيا
Dacarbazine	أستراليا, إيران, الدنمارك, السويد, الهند, الولايات المتحدة, ايرلندا, بريطانيا العظمي, بلجيكا, زيلاندا الجديدة, كندا
Dacarex	الهند, بيرو
Dacarin	الهند
Dacarpalm	بيرو
Dacarzine	الهند
Dacatic	فنلندا
Dacin	سويسرا
Dacmed	الهند
Daracina	كولومبيا
Deticene	إيطاليا, العربية السعودية, تونس, فرنسا, هولندا, يونان
Detilem	المكسيك
Detimedac	ألمانيا, كولومبيا
DTI	ماليزيا
DTIC	أستراليا, السويد, النمسا, الولايات المتحدة, بريطانيا العظمي, زيلاندا الجديدة
Fauldetic	البرتغال
Ifadac	المكسيك
Oncocarbil	الأرجنتين, الإكوادور, بيرو
Tiferomed	المكسيك

مراجع : Dacarbazine

	نوع	منشور
3	مجلة	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26	مجلة	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
40	مجلة	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
57	مجلة	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	مجلة	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	مجلة	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	مجلة	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	مجلة	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
184	مجلة	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	مجلة	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	مجلة	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	مجلة	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	مجلة	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	مجلة	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	مجلة	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	مجلة	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
353	مجلة	Lunn G, Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm 1987 ; 44: 2519-2524.
492	مجلة	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
860	مجلة	Nelson RW, Young R, Lamnin M. Visual incompatibility of dacarbazine and heparin. Am J Hosp Pharm 1987 ; 44: 2028.
905	مجلة	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1383	مجلة	Stevens MFG, Peatey L. Photodegradation of solutions of the antitumour drug DTIC. J Pharm Pharmacol 1978 ; 30: 47P.
1410	مجلة	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1501	مجلة	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1635	مجلة	El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107	مجلة	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
3266	مختبر	Lipomed Laboratories Dacarbazine solutions: In Use stability of dacarbazine lipomed® Lipomed 2011
3267	مختبر	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3540	مختبر	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3605	مختبر	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010

Mentions Légales